BCYRN1 and cancer: However, no systematic review has been conducted so far on the pan-cancer data of BCYRN1. To this end, we performed a meta-analysis of the relevant studies to further evaluate whether BCYRN1 is a reliable prognostic biomarker and therapeutic target for different cancers by evaluating the correlation between BCYRN1 expression levels and cancer-related clinicopathological features and patient prognosis.